
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7339926/publications.pdf Version: 2024-02-01



Μανιίει δαμάδρες

#	Article	IF	CITATIONS
1	Adipose Tissueâ€Derived Mesenchymal Stem Cells Have In Vivo Immunosuppressive Properties Applicable for the Control of the Graftâ€Versusâ€Host Disease. Stem Cells, 2006, 24, 2582-2591.	3.2	649
2	Effects of an Intrahospital Exercise Program Intervention for Children with Leukemia. Medicine and Science in Sports and Exercise, 2007, 39, 13-21.	0.4	153
3	Mesenchymal stem cells: biological properties and clinical applications. Expert Opinion on Biological Therapy, 2010, 10, 1453-1468.	3.1	147
4	Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Therapy, 2010, 17, 476-483.	4.6	126
5	Benefits of Intrahospital Exercise Training after Pediatric Bone Marrow Transplantation. International Journal of Sports Medicine, 2008, 29, 439-446.	1.7	99
6	Exercise during Hematopoietic Stem Cell Transplant Hospitalization in Children. Medicine and Science in Sports and Exercise, 2010, 42, 1045-1053.	0.4	93
7	Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood, 2019, 133, 2291-2304.	1.4	87
8	Functional Capacity of Children with Leukemia. International Journal of Sports Medicine, 2008, 29, 163-167.	1.7	76
9	A phase I/II trial of interleukin-15–stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. Cytotherapy, 2015, 17, 1594-1603.	0.7	69
10	Physical activity during treatment in children with leukemia: a pilot study. Applied Physiology, Nutrition and Metabolism, 2006, 31, 407-413.	1.9	67
11	EARLY-PHASE ADAPTATIONS TO INTRAHOSPITAL TRAINING IN STRENGTH AND FUNCTIONAL MOBILITY OF CHILDREN WITH LEUKEMIA. Journal of Strength and Conditioning Research, 2007, 21, 173-177.	2.1	64
12	KIR–HLA receptorâ€ligand mismatch associated with a graftâ€versusâ€tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatric Blood and Cancer, 2009, 53, 120-124.	1.5	64
13	Exercise Training and Cytokines in Breast Cancer Survivors. International Journal of Sports Medicine, 2011, 32, 461-467.	1.7	63
14	Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells. Cancer Letters, 2016, 371, 161-170.	7.2	61
15	Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients. Bone Marrow Transplantation, 2016, 51, 13-26.	2.4	60
16	First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors. Molecular Therapy, 2020, 28, 1033-1042.	8.2	57
17	Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia. Leukemia, 2012, 26, 2360-2366.	7.2	55
18	Detection of occult cerebrospinal fluid involvement during maintenance therapy identifies a group of children with acute lymphoblastic leukemia at high risk for relapse. American Journal of Hematology, 2013, 88, 359-364.	4.1	54

#	Article	IF	CITATIONS
19	Mobilisation of mesenchymal cells into blood in response to skeletal muscle injury. British Journal of Sports Medicine, 2006, 40, 719-722.	6.7	53
20	Human CD34+ cell preparations contain over 100-fold greater NOD/SCID mouse engrafting capacity than do CD34â^ cell preparations. Experimental Hematology, 2001, 29, 910-921.	0.4	49
21	Tnk1: a novel intracellular tyrosine kinase gene isolated from human umbilical cord blood CD34+/Lin-/CD38- stem/progenitor cells. Oncogene, 1996, 12, 903-13.	5.9	49
22	Hybrid Enzymeâ€Polymeric Capsules/Mesoporous Silica Nanodevice for In Situ Cytotoxic Agent Generation. Advanced Functional Materials, 2014, 24, 4625-4633.	14.9	48
23	Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors. Cancer Gene Therapy, 2005, 12, 341-349.	4.6	46
24	Muscling In on Cancer. New England Journal of Medicine, 2016, 375, 892-894.	27.0	44
25	A new targeting agent for the selective drug delivery of nanocarriers for treating neuroblastoma. Journal of Materials Chemistry B, 2015, 3, 4831-4842.	5.8	43
26	Chemokines and relapses in childhood acute lymphoblastic leukemia: A role in migration and in resistance to antileukemic drugs. Blood Cells, Molecules, and Diseases, 2015, 55, 220-227.	1.4	39
27	Mesenchymal Stromal Cells Derived from the Bone Marrow of Acute Lymphoblastic Leukemia Patients Show Altered BMP4 Production: Correlations with the Course of Disease. PLoS ONE, 2014, 9, e84496.	2.5	39
28	Ex VivoCulture of Cord Blood CD34+Cells Expands Progenitor Cell Numbers, Preserves Engraftment Capacity in Nonobese Diabetic/Severe Combined Immunodeficient Mice, and Enhances Retroviral Transduction Efficiency. Human Gene Therapy, 1999, 10, 2927-2940.	2.7	38
29	Early evaluation of immune reconstitution following allogeneic CD3/CD19-depleted grafts from alternative donors in childhood acute leukemia. Bone Marrow Transplantation, 2012, 47, 1419-1427.	2.4	37
30	Mature human hematopoietic cells in donor bone marrow complicate interpretation of stem/progenitor cell assays in xenogeneic hematopoietic chimeras. Experimental Hematology, 1998, 26, 332-44.	0.4	37
31	NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL. Leukemia, 2018, 32, 633-644.	7.2	35
32	Biology of CD34+CD38-Cells in Lymphohematopoiesis. Leukemia and Lymphoma, 1998, 31, 285-293.	1.3	34
33	Quantity and quality of engrafting cells in cord blood and autologous mobilized peripheral blood. Biology of Blood and Marrow Transplantation, 1999, 5, 69-76.	2.0	34
34	Graft Manipulation and Reduced-intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation From Mismatched Unrelated and Mismatched/Haploidentical Related Donors in Pediatric Leukemia Patients. Journal of Pediatric Hematology/Oncology, 2010, 32, e85-e90.	0.6	34
35	Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia. British Journal of Cancer, 2017, 117, 256-265.	6.4	34
36	Donor age matters in T-cell depleted haploidentical hematopoietic stem cell transplantation in pediatric patients: Faster immune reconstitution using younger donors. Leukemia Research, 2017, 57, 60-64.	0.8	33

#	Article	IF	CITATIONS
37	Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy. Cancer Research, 2018, 78, 4891-4901.	0.9	33
38	Peripheral blood progenitor cell collection adverse events for childhood allogeneic donors: variables related to the collection and safety profile. British Journal of Haematology, 2009, 144, 909-916.	2.5	31
39	Delayed engraftment of nonobese diabetic/severe combined immunodeficient mice transplanted with ex vivo-expanded human CD34(+) cord blood cells. Blood, 1999, 93, 1097-105.	1.4	31
40	Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology. Oncolytic Virotherapy, 2015, 4, 149.	6.0	30
41	Megatherapy in children with high-risk Ewing's sarcoma in first complete remission. Bone Marrow Transplantation, 1998, 21, 795-799.	2.4	29
42	Allogeneic hematopoietic transplantation using haploidentical donor vs. unrelated cord blood donor in pediatric patients: a single-center retrospective study. European Journal of Haematology, 2011, 87, 46-53.	2.2	29
43	Exercise training can induce cardiac autophagy at end-stage chronic conditions: Insights from a graft-versus-host-disease mouse model. Brain, Behavior, and Immunity, 2014, 39, 56-60.	4.1	29
44	Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts. Bone Marrow Transplantation, 2016, 51, 1211-1216.	2.4	29
45	Ex vivo expansion of umbilical cord blood (UCB) CD34+ cells alters the expression and function of α4β1 and α5β1 integrins. British Journal of Haematology, 2001, 115, 213-221.	2.5	28
46	Preliminary Findings of a 4-Month Intrahospital Exercise Training Intervention on IGFs and IGFBPs in Children with Leukemia. Journal of Strength and Conditioning Research, 2010, 24, 1292-1297.	2.1	28
47	A Role for the CXCR3/CXCL10 Axis in Rasmussen Encephalitis. Pediatric Neurology, 2013, 49, 451-457.e1.	2.1	28
48	The NFKB Inducing Kinase Modulates Hematopoiesis During Stress. Stem Cells, 2015, 33, 2825-2837.	3.2	28
49	IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia. Blood, 2019, 134, 2171-2182.	1.4	28
50	Intrahospital supervised exercise training: a complementary tool in the therapeutic armamentarium against childhood leukemia. Leukemia, 2005, 19, 1334-1337.	7.2	26
51	Extracorporeal photochemotherapy for steroid-refractory graft-versus-host disease in low-weight pediatric patients. Immunomodulatory effects and clinical outcome. Haematologica, 2008, 93, 1278-1280.	3.5	26
52	Systemic oncolytic adenovirus delivered in mesenchymal carrier cells modulate tumor infiltrating immune cells and tumor microenvironment in mice with neuroblastoma. Oncotarget, 2020, 11, 347-361.	1.8	26
53	Flt3high and Flt3low CD34+ progenitor cells isolated from human bone marrow are functionally distinct. Blood, 1998, 91, 1947-58.	1.4	25
54	Full donor chimerism by day 30 after allogeneic peripheral blood progenitor cell transplantation is associated with a low risk of relapse in pediatric patients with hematological malignancies. Leukemia, 2005, 19, 504-506.	7.2	24

#	Article	IF	CITATIONS
55	Analysis of Clinical Outcome and Survival in Pediatric Patients Undergoing Extracorporeal Photopheresis for the Treatment of Steroid-refractory GVHD. Journal of Pediatric Hematology/Oncology, 2010, 32, 589-593.	0.6	24
56	Effects of local administration of allogenic adipose tissue-derived mesenchymal stem cells on functional recovery in experimental traumatic brain injury. Brain Injury, 2015, 29, 1497-1510.	1.2	24
5 <b>7</b>	Pediatric experience with autologous peripheral blood progenitor cell transplantation: influence of CD34+ cell dose in engraftment kinetics. Bone Marrow Transplantation, 1996, 18, 699-703.	2.4	24
58	Chimerism after allogeneic hematopoietic cell transplantation in childhood acute lymphoblastic leukemia. Bone Marrow Transplantation, 1996, 18, 1161-5.	2.4	24
59	Blood Dendritic Cells Suppress NK Cell Function and Increase the Risk of Leukemia Relapse after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 598-607.	2.0	23
60	Exercise Benefits in Chronic Graft versus Host Disease. Medicine and Science in Sports and Exercise, 2013, 45, 1703-1711.	0.4	23
61	Optimal Effector Functions in Human Natural Killer Cells Rely upon Autocrine Bone Morphogenetic Protein Signaling. Cancer Research, 2014, 74, 5019-5031.	0.9	22
62	Engraftment syndrome after autologous peripheral blood progenitor cell transplantation in pediatric patients: a prospective evaluation of risk factors and outcome. Bone Marrow Transplantation, 2004, 34, 1051-1055.	2.4	20
63	CAR T cell therapy in B-cell acute lymphoblastic leukaemia: Insights from mathematical models. Communications in Nonlinear Science and Numerical Simulation, 2021, 94, 105570.	3.3	20
64	Serum sRAGE as a Potential Biomarker for Pediatric Bronchiolitis: A Pilot Study. Lung, 2015, 193, 19-23.	3.3	18
65	Mesenchymal Stem Cells are of Recipient Origin in Pediatric Transplantations Using Umbilical Cord Blood, Peripheral Blood, or Bone Marrow. Journal of Pediatric Hematology/Oncology, 2007, 29, 388-392.	0.6	17
66	PEG-pHPMAm-based polymeric micelles loaded with doxorubicin-prodrugs in combination antitumor therapy with oncolytic vaccinia viruses. Polymer Chemistry, 2014, 5, 1674-1681.	3.9	17
67	High-Dimensional Analysis of Single-Cell Flow Cytometry Data Predicts Relapse in Childhood Acute Lymphoblastic Leukaemia. Cancers, 2021, 13, 17.	3.7	17
68	In vivo engraftment potential of clinical hematopoietic grafts. Journal of Investigative Medicine, 1998, 46, 303-11.	1.6	17
69	Human Hematopoietic Stem/Progenitor Cells Generate CD5 <sup>+</sup> B Lymphoid Cells in NOD/SCID Mice. Stem Cells, 1999, 17, 242-252.	3.2	16
70	Clinical and economic comparison of allogeneic peripheral blood progenitor cell and bone marrow transplantation for acute lymphoblastic leukemia in children. Bone Marrow Transplantation, 2000, 26, 269-273.	2.4	16
71	Impaired Condensin Complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL. Blood, 2020, 136, 313-327.	1.4	16
72	Mesenchymal stem cells derived from low risk acute lymphoblastic leukemia patients promote NK cell antitumor activity. Cancer Letters, 2015, 363, 156-165.	7.2	15

#	Article	IF	CITATIONS
73	Molecular Scaffolds as Doubleâ€Targeting Agents For the Diagnosis and Treatment of Neuroblastoma. Angewandte Chemie - International Edition, 2019, 58, 3067-3072.	13.8	15
74	Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis. Scientific Reports, 2020, 10, 19189.	3.3	15
75	COMPARISONS OF ALLOREACTIVE POTENTIAL OF CLINICAL HEMATOPOIETIC GRAFTS1. Transplantation, 1999, 68, 628-635.	1.0	15
76	Complicated Pulmonary Aspergillosis with Pneumothorax and Pneumopericardium in a Child with Acute Lymphoblastic Leukemia. Pediatric Hematology and Oncology, 1995, 12, 195-199.	0.8	14
77	A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children. Bone Marrow Transplantation, 2004, 34, 1077-1081.	2.4	14
78	Defining "poor mobilizer―in pediatric patients who need an autologous peripheral blood progenitor cell transplantation. Cytotherapy, 2013, 15, 132-137.	0.7	14
79	Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia. Journal of Clinical Investigation, 2021, 131, .	8.2	14
80	G-CSF after autologous bone marrow transplantation for malignant diseases in children. Spanish Working Party for Bone Marrow Transplantation in Children. Bone Marrow Transplantation, 1995, 15, 349-51.	2.4	14
81	CBFbeta-SMMHC, expressed in M4eo acute myeloid leukemia, reduces p53 induction and slows apoptosis in hematopoietic cells exposed to DNA-damaging agents. Blood, 1998, 92, 4344-52.	1.4	14
82	Understanding graft-versus-host disease. Preliminary findings regarding the effects of exercise in affected patients. Exercise Immunology Review, 2015, 21, 80-112.	0.4	14
83	Haploidentical Stem Cell Transplantation in Children With Hematological Malignancies Using αβ+ T-Cell Receptor and CD19+ Cell Depleted Grafts: High CD56dim/CD56bright NK Cell Ratio Early Following Transplantation Is Associated With Lower Relapse Incidence and Better Outcome. Frontiers in Immunology, 2019, 10, 2504.	4.8	13
84	ALLOGENEIC CORD BLOOD TRANSPLANTATION IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES: A Long-Term Follow-Up Single-Center Study. Pediatric Hematology and Oncology, 2009, 26, 165-174.	0.8	12
85	G9a Correlates with VLA-4 Integrin and Influences the Migration of Childhood Acute Lymphoblastic Leukemia Cells. Cancers, 2018, 10, 325.	3.7	12
86	Genetic and Immune Changes Associated with Disease Progression under the Pressure of Oncolytic Therapy in A Neuroblastoma Outlier Patient. Cancers, 2020, 12, 1104.	3.7	12
87	Multiple particle tracking analysis in isolated nuclei reveals the mechanical phenotype of leukemia cells. Scientific Reports, 2020, 10, 6707.	3.3	12
88	Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept. Cancers, 2021, 13, 703.	3.7	12
89	Efficient and nontoxic adenoviral purging method for autologous transplantation in breast cancer patients. Cancer Research, 2002, 62, 5013-8.	0.9	12
90	PBSC collection in extremely low weight infants: a single-center experience. Cytotherapy, 2007, 9, 356-361.	0.7	11

MANUEL RAMÂREZ

#	Article	IF	CITATIONS
91	Effects of Exercise Interventions in Graft-Versus-Host Disease Models. Cell Transplantation, 2013, 22, 2409-2420.	2.5	11
92	Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia. Leukemia Research, 2002, 26, 817-820.	0.8	10
93	Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLAâ€matched allogeneic stem cell transplantation in childhood leukaemia patients. British Journal of Haematology, 2008, 140, 340-343.	2.5	10
94	The choroid plexus stroma constitutes a sanctuary for paediatric B  ell precursor acute lymphoblastic leukaemia in the central nervous system. Journal of Pathology, 2020, 252, 189-200.	4.5	10
95	The Netrin-1-Neogenin-1 signaling axis controls neuroblastoma cell migration via integrin-β1 and focal adhesion kinase activation. Cell Adhesion and Migration, 2021, 15, 58-73.	2.7	10
96	Fast H3K9 methylation promoted by CXCL12 contributes to nuclear changes and invasiveness of T-acute lymphoblastic leukemia cells. Oncogene, 2022, 41, 1324-1336.	5.9	10
97	Oncolytic virotherapy for neuroblastoma. Discovery Medicine, 2010, 10, 387-93.	0.5	10
98	Engraftment kinetics of human CD34+ cells from cord blood and mobilized peripheral blood co-transplanted into NOD/SCID mice. Bone Marrow Transplantation, 2005, 35, 271-275.	2.4	8
99	Mobilisation of mesenchymal cells in cardiac patients: is intense exercise necessary?. British Journal of Sports Medicine, 2009, 43, 221-223.	6.7	8
100	Dopamine Mobilizes Mesenchymal Progenitor Cells Through D2-Class Receptors and Their PI3K/AKT Pathway. Stem Cells, 2014, 32, 2529-2538.	3.2	8
101	Superselective Intracerebral Catheterization for Administration of Oncolytic Virotherapy in a Case of Diffuse Intrinsic Pontine Glioma. Journal of Pediatric Hematology/Oncology, 2014, 36, e430-e432.	0.6	8
102	The Netrin-4/Laminin Î $^3$ 1/Neogenin-1 complex mediates migration in SK-N-SH neuroblastoma cells. Cell Adhesion and Migration, 2019, 13, 33-40.	2.7	8
103	A Mathematical Description of the Bone Marrow Dynamics during CAR T-Cell Therapy in B-Cell Childhood Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences, 2021, 22, 6371.	4.1	8
104	Nuclear factor-Â B inducing kinase is required for graft-versus-host disease. Haematologica, 2010, 95, 2111-2118.	3.5	7
105	CD64 on monocytes and granulocytes in severe acute bronchiolitis: Pilot study on its usefulness as a bacterial infection biomarker. Journal of Leukocyte Biology, 2018, 103, 965-971.	3.3	7
106	Immune-Mediated Mechanisms in the Pathogenesis of Hopkins Syndrome. Pediatric Neurology, 2012, 47, 373-374.	2.1	6
107	CBFβ-SMMHC, Expressed in M4eo Acute Myeloid Leukemia, Reduces p53 Induction and Slows Apoptosis in Hematopoietic Cells Exposed to DNA-Damaging Agents. Blood, 1998, 92, 4344-4352.	1.4	6
108	Clinical relevance of T-cell receptor delta gene rearrangements in childhood B-precursor cell acute lymphoblastic leukaemia. British Journal of Haematology, 1997, 99, 308-313.	2.5	5

#	Article	IF	CITATIONS
109	Circulating soluble RAGE and cell surface RAGE on peripheral blood mononuclear cells in healthy children. Journal of Pediatric Endocrinology and Metabolism, 2018, 31, 649-654.	0.9	5
110	Outcome of childhood leukaemia survivors and necrosis of the femoral head treated with autologous mesenchymal stem cells. Clinical and Translational Oncology, 2018, 20, 584-590.	2.4	5
111	Engraftment characterization of risk-stratified AML patients in NSGS mice. Blood Advances, 2021, 5, 4842-4854.	5.2	5
112	Cord Blood Transplantation: A Promising Future. Pediatrics, 1997, 99, 475-475.	2.1	4
113	Molecular Scaffolds as Doubleâ€Targeting Agents For the Diagnosis and Treatment of Neuroblastoma. Angewandte Chemie, 2019, 131, 3099-3104.	2.0	4
114	TYK2 Variants in B-Acute Lymphoblastic Leukaemia. Genes, 2020, 11, 1434.	2.4	4
115	Dynamical properties of feedback signalling in B lymphopoiesis: A mathematical modelling approach. Journal of Theoretical Biology, 2021, 522, 110685.	1.7	4
116	MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia. Frontiers in Cell and Developmental Biology, 2021, 9, 695225.	3.7	4
117	Transplantation of marrow cells from children with standard risk-acute lymphoblastic leukemia at the end of therapy into NOD/SCID mice for detecting residual leukemic cells with in vivo growth potential. Leukemia Research, 2003, 27, 1153-1157.	0.8	3
118	Enrichment of neural-related genes in human mesenchymal stem cells from neuroblastoma patients. International Journal of Molecular Medicine, 2012, 30, 365-373.	4.0	3
119	Plerixaforâ€based mobilization in pediatric healthy donors with unfavorable donor/recipient body weight ratio resulted in a better <scp>CD34</scp> <sup>+</sup> collection yield: A retrospective analysis. Journal of Clinical Apheresis, 2021, 36, 78-86.	1.3	3
120	In Vitro and In Vivo Immunomodulatory Effects of Mesenchymal Stem Cells from Adipose Tissue Blood, 2005, 106, 3098-3098.	1.4	3
121	162: Fludarabine-based reduced-intensity conditioning for allogeneic transplantation in children with malignant and non-malignant diseases. Biology of Blood and Marrow Transplantation, 2007, 13, 61.	2.0	2
122	Chemokines in Leukemic Infiltration of the Central Nervous System in Childhood Acute Lymphoblastic Leukemia Blood, 2009, 114, 1627-1627.	1.4	2
123	G-CSF-mobilized PBSCT in children with AML in first complete remission. Bone Marrow Transplantation, 1999, 23, 975-976.	2.4	1
124	Intentional induction of immune-hematopoietic mixed chimerism as a platform for early cellular therapy in pediatric leukemia patients after allogeneic transplantation: Enhancing GvL effect while avoiding GvHD. Biology of Blood and Marrow Transplantation, 2006, 12, 53-54.	2.0	1
125	sRAGE as severe acute bronchiolitis biomarker, prospective observational study. Pediatric Pulmonology, 2020, 55, 3429-3436.	2.0	1
126	Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia. Journal of Personalized Medicine, 2020, 10, 244.	2.5	1

MANUEL RAMÂREZ

#	Article	IF	CITATIONS
127	Increased Hypothalamic Anti-Inflammatory Mediators in Non-Diabetic Insulin Receptor Substrate 2-Deficient Mice. Cells, 2021, 10, 2085.	4.1	1
128	Clinical Proteomics in Cancer Research. Current Proteomics, 2013, 10, 179-191.	0.3	1
129	Immunomagnetic T Cell Depletion: an Analysis of Variables Affecting Final Cell Yield. Clinical Laboratory, 2016, 62, 1243-1248.	0.5	1
130	The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia. Cancers, 2022, 14, 1593.	3.7	1
131	Mobilization with highâ€dose granulocyte colonyâ€stimulating factor alone at 12 μg/kg twice a day in highâ€risk pediatric patients: A retrospective analysis of the experience in a single center. Journal of Clinical Apheresis, 2022, 37, 420-429.	1.3	1
132	T-Cell Depleted Haploidentical Transplantation in Children With Hematological Malignancies: A Comparison Between CD3+/CD19+ and TCRαβ+/CD19+ Depletion Platforms. Frontiers in Oncology, 0, 12, .	2.8	1
133	A Role For NF-KB Inducing Kinase (NIK) In Graft Versus Host Reactions. Biology of Blood and Marrow Transplantation, 2009, 15, 118.	2.0	0
134	Spontaneous Resolution of Hypereosinophilic Syndrome in an Infant Without Treatment. Journal of Pediatric Hematology/Oncology, 2012, 34, 450-452.	0.6	0
135	CitometrÃa de flujo: qué puede aportar al diagnóstico hematológico en pediatrÃa. Anales De Pediatria Continuada, 2012, 10, 282-285.	0.1	0
136	Mesenchymal Stem Cells for the Treatment of Cancer. , 2012, , 177-183.		0
137	Early clinical trials in paediatric oncology in Spain: A nationwide perspective. Anales De PediatrÃa (English Edition), 2017, 87, 155-163.	0.2	0
138	Immunotherapy with CAR-T cells in paediatric haematology-oncology. Anales De PediatrÃa (English) Tj ETQq0 0 C	) rgBT /Ov	erlock 10 Tf 5
139	Changes in L-Selectin Expression by T Lymphocytes after Extracorporeal Photochemotherapy Blood, 2007, 110, 1961-1961.	1.4	0

140	Acute lymphoblastic leukemia cells are able to infiltrate the brain subventricular zone stem cell niche and impair neurogenesis. Haematologica, 2022, , .	3.5	0
141	High BMP4 expression in low/intermediate risk BCP-ALL identifies children with poor outcome. Blood, 2022, , .	1.4	0